Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Return on Sales (2021 - 2025)

Inmune Bio (INMB) has disclosed Return on Sales for 5 consecutive years, with 947.66% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 209770.0% to 947.66% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 947.66% through Dec 2025, up 209770.0% year-over-year, with the annual reading at 947.66% for FY2025, 209770.0% up from the prior year.
  • Return on Sales hit 947.66% in Q4 2025 for Inmune Bio, up from 1027.52% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 39.74% in Q1 2022 to a low of 4782.75% in Q2 2021.
  • Historically, Return on Sales has averaged 828.13% across 5 years, with a median of 421.91% in 2022.
  • Biggest five-year swings in Return on Sales: soared 438350bps in 2022 and later tumbled -274611bps in 2024.
  • Year by year, Return on Sales stood at 55.4% in 2021, then fell by -5bps to 58.16% in 2022, then plummeted by -414bps to 299.25% in 2023, then tumbled by -918bps to 3045.36% in 2024, then soared by 69bps to 947.66% in 2025.
  • Business Quant data shows Return on Sales for INMB at 947.66% in Q4 2025, 1027.52% in Q3 2025, and 1124.58% in Q2 2025.